INNOVACAPInnova Captab Ltd.

₹831.35-0.66%

Market Cap

₹4,792.87 Cr

Stock P/E

36.93

ROCE

19.06%

ROE

17.04%

Book Value

₹173.08

Financials

YoY Net Sales

EPS Growth

Operating Margin

You might have missed

No Recent News

No recent news available for this stock.

Shareholding

Holdings

Distribution

Promoter

Institution

Public

Others

From Last Concall

POSITIVES

•
Strong revenue momentum with healthy topline growth and improving profitability.
•
Branded generics momentum delivering materially higher growth and expanding market reach.

NEGATIVES

•
API price volatility impacting Jammu ramp-up and revenue visibility.
•
Jammu ramp-up risk and ongoing onboarding create execution uncertainty.

Peers Summary

Sector Leader

Innova Captab Ltd. shows moderate growth and profitability metrics relative to its peers in the Pharmaceuticals & Drugs sector. While it has a reasonable debt level, its high PE ratio suggests it may be overvalued compared to its profitability. Companies like Cipla Ltd. and Mankind Pharma Ltd. demonstrate strong performance, indicating potential value picks for investors.

Key Points

• Innova Captab Ltd. has a low revenue growth rate YoY (0%) but a robust 3-Year growth (38.09%).
• Cipla Ltd. offers the lowest PE ratio (23.73) and strong profitability metrics, indicating it is a value pick.
• Divi's Laboratories Ltd. has the highest PE (73.20) and low revenue growth, marking it as overvalued.
• Mankind Pharma Ltd. exhibits impressive revenue growth (18.12% YoY), making it a strong contender for growth investment.

Top Performers

Cipla Ltd.

Lowest PE ratio (23.73) and strong profitability (ROE 16.63%) make it a value pick.

Mankind Pharma Ltd.

Highest YoY revenue growth (18.12%) with strong profitability (ROE 23.15%).

Explore

Watchlists

Command Palette